HUP0200014A3 - Pharmaceutical aerosol compositions containing fluoroalkanes, budesonide and formoterol - Google Patents

Pharmaceutical aerosol compositions containing fluoroalkanes, budesonide and formoterol

Info

Publication number
HUP0200014A3
HUP0200014A3 HU0200014A HUP0200014A HUP0200014A3 HU P0200014 A3 HUP0200014 A3 HU P0200014A3 HU 0200014 A HU0200014 A HU 0200014A HU P0200014 A HUP0200014 A HU P0200014A HU P0200014 A3 HUP0200014 A3 HU P0200014A3
Authority
HU
Hungary
Prior art keywords
formoterol
budesonide
compositions containing
aerosol compositions
pharmaceutical aerosol
Prior art date
Application number
HU0200014A
Other languages
English (en)
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22802357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0200014(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of HUP0200014A2 publication Critical patent/HUP0200014A2/hu
Publication of HUP0200014A3 publication Critical patent/HUP0200014A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C66/00—General aspects of processes or apparatus for joining preformed parts
    • B29C66/70—General aspects of processes or apparatus for joining preformed parts characterised by the composition, physical properties or the structure of the material of the parts to be joined; Joining with non-plastics material
    • B29C66/71—General aspects of processes or apparatus for joining preformed parts characterised by the composition, physical properties or the structure of the material of the parts to be joined; Joining with non-plastics material characterised by the composition of the plastics material of the parts to be joined

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0200014A 1998-12-18 1999-12-17 Pharmaceutical aerosol compositions containing fluoroalkanes, budesonide and formoterol HUP0200014A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/215,280 US6004537A (en) 1998-12-18 1998-12-18 Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol

Publications (2)

Publication Number Publication Date
HUP0200014A2 HUP0200014A2 (hu) 2002-06-29
HUP0200014A3 true HUP0200014A3 (en) 2005-06-28

Family

ID=22802357

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200014A HUP0200014A3 (en) 1998-12-18 1999-12-17 Pharmaceutical aerosol compositions containing fluoroalkanes, budesonide and formoterol

Country Status (12)

Country Link
US (1) US6004537A (hu)
EP (1) EP1140059A2 (hu)
JP (1) JP4921639B2 (hu)
AR (1) AR021922A1 (hu)
AU (1) AU776257B2 (hu)
BR (1) BR9916829A (hu)
CA (1) CA2355932C (hu)
CZ (1) CZ20012216A3 (hu)
HU (1) HUP0200014A3 (hu)
PL (1) PL348809A1 (hu)
TW (1) TW574038B (hu)
WO (1) WO2000035441A2 (hu)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4003272A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
EE03509B2 (et) * 1995-06-27 2015-02-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Stabiilsed ravimikompositsioonid kandegaasita aerosoolide saamiseks
GB9616237D0 (en) * 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6290930B1 (en) * 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1313553B1 (it) * 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
CA2317999C (en) * 1999-09-11 2004-11-09 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
ES2238334T3 (es) * 1999-12-24 2005-09-01 Glaxo Group Limited Formulacion farmaceutica en aerosol de salmeterol y propionato de fluticasona.
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
ME00220B (me) 2000-05-22 2010-10-10 Chiesi Farm Spa Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
SI1273292T1 (en) * 2001-07-02 2004-12-31 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
ME00077B (me) * 2002-03-01 2010-06-10 Chiesi Farm Spa Formoterol najfiniji preparat
GB0207899D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
DK1542904T3 (da) * 2002-08-27 2008-04-21 Schering Corp Fremgangsmåde til fremstilling af formuleringer til en inhalator med målte doser
SE0203376D0 (sv) * 2002-11-15 2002-11-15 Astrazeneca Ab New process
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
AR041873A1 (es) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
TWI657070B (zh) * 2005-06-24 2019-04-21 美商哈尼威爾國際公司 含有經氟取代之烯烴之組合物及其用途
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
CN101652123A (zh) * 2007-02-09 2010-02-17 先灵公司 稳定的药物气雾剂
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP3311820A1 (en) * 2008-02-26 2018-04-25 Sunovion Respiratory Development Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
CA2763939A1 (en) 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems
EP2512438B1 (en) 2009-12-16 2017-01-25 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
TWI399202B (zh) 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
CN102362860A (zh) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
ITMI20130571A1 (it) 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
EP3515432B1 (en) 2016-09-19 2021-08-25 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising glycopyrrolate
JP7268965B2 (ja) * 2018-06-05 2023-05-08 アース製薬株式会社 定量噴射型エアゾール製品および消臭方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7708731A (nl) * 1976-08-13 1978-02-15 Montedison Spa Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
DE69105212T2 (de) * 1990-10-18 1995-03-23 Minnesota Mining & Mfg Aerosolzubereitung, die beclometason 17,21-dipropionat enthält.
MX9203481A (es) * 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
AU2178392A (en) * 1991-06-12 1993-01-12 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
DE4123663A1 (de) * 1991-07-17 1993-01-21 Schwabe Willmar Gmbh & Co Aerosol-zubereitung und verwendung eines treibmittels dafuer
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
CA2356145A1 (en) * 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
DK0550031T3 (da) * 1991-12-31 1996-08-26 Solvay Medicinsk aerosolformulering
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
GB9616237D0 (en) * 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
SE9603669D0 (sv) * 1996-10-08 1996-10-08 Astra Ab New combination
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use

Also Published As

Publication number Publication date
JP4921639B2 (ja) 2012-04-25
WO2000035441A3 (en) 2000-10-26
WO2000035441A2 (en) 2000-06-22
CA2355932A1 (en) 2000-06-22
JP2002532418A (ja) 2002-10-02
BR9916829A (pt) 2001-10-23
AU2194900A (en) 2000-07-03
AR021922A1 (es) 2002-09-04
AU776257B2 (en) 2004-09-02
EP1140059A2 (en) 2001-10-10
PL348809A1 (en) 2002-06-17
US6004537A (en) 1999-12-21
HUP0200014A2 (hu) 2002-06-29
CZ20012216A3 (cs) 2002-04-17
TW574038B (en) 2004-02-01
CA2355932C (en) 2009-06-23

Similar Documents

Publication Publication Date Title
HUP0200014A3 (en) Pharmaceutical aerosol compositions containing fluoroalkanes, budesonide and formoterol
IL149362A0 (en) Aerosol composition comprising formoterol
ATE260093T1 (de) Aerosoldruckdosiergeräte und aerosolarzneizusammensetzungen
IL134773A0 (en) New use for budesonide and formoterol
HUP0103108A3 (en) Use of composition comprising formoterol and budesonide for the prevention of an acute condition of asthma
IL139087A0 (en) Pharmaceutical aerosol formulation
HK1042429A1 (en) Combinations of formoterol and fluticasone propionate for asthma.
SI1381346T1 (sl) Farmacevtski sestavki, ki vsebujejo formoterol
HUP0103884A3 (en) Arylsulfonanilide urea-derivatives, pharmaceutical compositions containing them and their use
SI1385494T1 (sl) Sestavki, ki vsebujejo formoterol in steroid, za dovajanje v pljuča
IL138280A0 (en) 20-KETO-11β-ARYLSTERIODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF
ZA974546B (en) Medicinal aerosol formulations of formoterol
IL140897A0 (en) Benzocycloheptene derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HUP0200066A3 (en) Pharmaceutical aerosol formulations containing fluoroalkanes and budesonide
HUP0000795A3 (en) Medicinal aerosol formulations comprising budesonide
IL146230A0 (en) 3α-HYDROXY-3β-METHOXYMETHYL-SUBSTITUTED STEROIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
AU4671601A (en) Medical combinations comprising formoterol and budesonide
IL137505A (en) Pharmaceutical compositions containing tramadol
HUP0104834A3 (en) Sulphonyloxazolamines, their use, pharmaceutical compositions containing them and their preparation
AU4853801A (en) Medical combination comprising salmeterol and budesonide
GB9803521D0 (en) New compounds and pharmaceutical compositions thereof
ZA200007646B (en) Inhalation of aerosol actives.
HUP0103006A3 (en) Substituted betha-diketones, pharmaceutical compositions containing them and their use
AU2001284287A1 (en) Pharmaceutical combination containing salmeterol and fluticasone
GB9814709D0 (en) Pharmaceutical aerosol formulation

Legal Events

Date Code Title Description
FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): SCHL?FER LASZLO, DANUBIA SZABADALMI ES VEDJEGY IRODA KFT., HU

Representative=s name: SZENTPETERI ZSOLT SZABADALMI UEGYVIVOE, S.B.G., HU

FH92 Termination of representative

Representative=s name: SCHL?FER LASZLO, DANUBIA SZABADALMI ES VEDJEGY, HU

HC9A Change of name, address

Owner name: IVAX RESEARCH, INC., US

Free format text: FORMER OWNER(S): BAKER NORTON PHARMACEUTICALS, INC., US; IVAX LABORATORIES, INC., US

FC4A Lapse of provisional application due to refusal